-
Posted by
Two Blokes Jul 1 -
Filed in
Stock
-
4 views
Novo Nordisk's fundamentals remain robust despite recent share price weakness, with strong sales and profit growth as well as a well-established pipeline. Concerns over CEO transition and compounding threats are overblown; FDA enforcement and strategic partnerships will redirect demand to branded Wegovy. An oral semaglutide approval later this year can help reignite share price momentum.
